Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
2.

Ganciclovir Therapeutic Drug Monitoring: A Case Series.

Märtson AG, Touw D, Damman K, Bakker M, Oude Lansink-Hartgring A, van der Werf T, Knoester M, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):107-110. doi: 10.1097/FTD.0000000000000598.

PMID:
30883503
3.

Tuberculosis-related Malnutrition: Public Health Implications.

Ter Beek L, Alffenaar JC, Bolhuis MS, van der Werf TS, Akkerman OW.

J Infect Dis. 2019 Mar 5. pii: jiz091. doi: 10.1093/infdis/jiz091. [Epub ahead of print]

PMID:
30835281
4.

Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02379-18. doi: 10.1128/AAC.02379-18. [Epub ahead of print]

PMID:
30782999
5.

Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat.

Dekkers BGJ, Bierman WFW, Touw DJ, Alffenaar JC.

AIDS. 2019 Feb 7. doi: 10.1097/QAD.0000000000002162. [Epub ahead of print] No abstract available.

PMID:
30741824
6.

Ganciclovir Therapeutic Drug Monitoring: A Case Series.

Märtson AG, Touw D, Damman K, Bakker M, Lansink-Hartgring AO, van der Werf T, Knoester M, Alffenaar JC.

Ther Drug Monit. 2019 Jan 25. doi: 10.1097/FTD.0000000000000598. [Epub ahead of print]

PMID:
30688869
7.

Levofloxacin pharmacokinetics and pharmacodynamics and outcome in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Eur Respir J. 2019 Jan 17. pii: 1802107. doi: 10.1183/13993003.02107-2018. [Epub ahead of print] No abstract available.

PMID:
30655280
8.

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.

Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):380-386. doi: 10.4103/ijmy.ijmy_143_18.

9.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
10.

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613.

PMID:
30496466
11.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
12.

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.

PMID:
30496455
13.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

14.

Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned.

Alffenaar JC, Tiberi S, Migliori GB.

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23. No abstract available.

PMID:
30477962
15.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

PMID:
30455232
16.

Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens.

Milliken E, de Zwart AES, Alffenaar JC, Marriott DJE, Riezebos-Brilman A, Schteinman A, Evans AM, Glanville AR, Verschuuren EAM, Reuter SE.

J Antimicrob Chemother. 2019 Mar 1;74(3):691-698. doi: 10.1093/jac/dky466.

PMID:
30452661
17.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2018 Nov 8. doi: 10.1007/s40262-018-0716-8. [Epub ahead of print] Review.

18.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

PMID:
30373800
19.

Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.

Gafar F, Arifin H, Jurnalis YD, Yani FF, Fitria N, Alffenaar JC, Wilffert B.

Pediatr Infect Dis J. 2019 Jan;38(1):50-53. doi: 10.1097/INF.0000000000002192.

PMID:
30234790
20.

Therapeutic Drug Monitoring: The Need for Practical Guidance.

Alffenaar JC, Heysell SK, Mpagama SG.

Clin Infect Dis. 2019 Mar 5;68(6):1065-1066. doi: 10.1093/cid/ciy787. No abstract available.

PMID:
30219826
21.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
22.

Invasive Candidiasis in the Elderly: Considerations for Drug Therapy.

Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC.

Drugs Aging. 2018 Sep;35(9):781-789. doi: 10.1007/s40266-018-0576-9. Review.

23.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

24.

Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin.

Boonstra JM, Jongedijk EM, Koster RA, Touw DJ, Alffenaar JC.

Bioanalysis. 2018 Jun 1;10(11):877-886. doi: 10.4155/bio-2017-0275. Epub 2018 Jun 4.

PMID:
29863416
25.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
26.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1755-1762. doi: 10.1093/jac/dky096.

27.

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC.

Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. No abstract available.

PMID:
29396032
28.

Lack of penetration of amikacin into saliva of tuberculosis patients.

van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. No abstract available.

PMID:
29326320
29.

New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Caño-Muñiz S, Anthony R, Niemann S, Alffenaar JC.

Clin Microbiol Rev. 2017 Nov 29;31(1). pii: e00060-17. doi: 10.1128/CMR.00060-17. Print 2018 Jan. Review.

30.

Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention.

Nguyen TVA, Anthony RM, Bañuls AL, Nguyen TVA, Vu DH, Alffenaar JC.

Clin Infect Dis. 2018 May 2;66(10):1625-1630. doi: 10.1093/cid/cix992.

PMID:
29126225
31.

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, Bolhuis MS, Alffenaar JC.

Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. Review.

32.

Risk factors contributing to a low darunavir plasma concentration.

Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, Alffenaar JC.

Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7.

33.

Treatment of Mycobacterium avium-intracellulare complex: a great leap forward.

Alffenaar JC, van Ingen J.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i1-i2. doi: 10.1093/jac/dkx310. No abstract available.

PMID:
28922812
34.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
35.

Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring.

van den Elsen SHJ, van der Laan T, Akkerman OW, van der Zanden AGM, Alffenaar JC, van Soolingen D.

J Clin Microbiol. 2017 Nov;55(11):3292-3293. doi: 10.1128/JCM.01248-17. Epub 2017 Aug 9. No abstract available.

36.

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

van Rijn SP, Srivastava S, Wessels MA, van Soolingen D, Alffenaar JC, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02039-16. doi: 10.1128/AAC.02039-16. Print 2017 Sep.

37.

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

Daskapan A, Dijkema D, de Weerd DA, Bierman WFW, Kosterink JGW, van der Werf TS, Alffenaar JC, Stienstra Y.

Br J Clin Pharmacol. 2017 Oct;83(10):2325-2329. doi: 10.1111/bcp.13366. Epub 2017 Aug 1.

38.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

39.

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.

Davies Forsman L, Bruchfeld J, Alffenaar JC.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700173. doi: 10.1183/13993003.00173-2017. Print 2017 Apr. No abstract available.

40.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
41.

Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.

Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, van der Werf TS, Akkerman OW.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601724. doi: 10.1183/13993003.01724-2016. Print 2017 Mar. No abstract available.

42.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

43.

Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems.

Koster RA, Veenhof H, Botma R, Hoekstra AT, Berger SP, Bakker SJ, Alffenaar JC, Touw DJ.

Bioanalysis. 2017 Apr;9(7):553-563. doi: 10.4155/bio-2016-0296. Epub 2017 Mar 16.

PMID:
28300419
44.

Statin Adjunctive Therapy for Tuberculosis Treatment.

Alffenaar JC, Akkerman OW, van Hest R.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):7004. doi: 10.1128/AAC.01836-16. Print 2016 Nov. No abstract available.

45.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

46.

Bioavailability of voriconazole in hospitalised patients.

Veringa A, Geling S, Span LF, Vermeulen KM, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JC.

Int J Antimicrob Agents. 2017 Feb;49(2):243-246. doi: 10.1016/j.ijantimicag.2016.10.010. Epub 2016 Nov 23.

PMID:
28012684
47.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
48.

Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients.

Veenhof H, Koster RA, Alffenaar JC, Berger SP, Bakker SJL, Touw DJ.

Transplantation. 2017 Jul;101(7):1727-1733. doi: 10.1097/TP.0000000000001591.

PMID:
27906832
49.

The effect of inflammation on voriconazole trough concentrations in children.

Ter Avest M, Veringa A, van den Heuvel ER, Kosterink JG, Schölvinck EH, Tissing WJ, Alffenaar JC.

Br J Clin Pharmacol. 2017 Mar;83(3):678-680. doi: 10.1111/bcp.13151. Epub 2016 Nov 9. No abstract available.

50.

Tumor Necrosis Factor-Alpha Inhibitor Etanercept Does Not Alter Methotrexate-Induced Gastrointestinal Mucositis in Rats.

Kuiken NSS, Rings EHHM, Alffenaar JC, Havinga R, Jurdzinski A, Groen AK, Tissing WJE.

J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):e28-e34. doi: 10.1097/MPG.0000000000001469.

PMID:
27861204

Supplemental Content

Loading ...
Support Center